Plus Therapeutics Inc share price logo

Plus Therapeutics Inc Share Price

NASDAQ: PSTV

Small Cap

$0.23

-0.02

(-6.79%)

as on

Plus Therapeutics Inc Stock Performance

as on March 28, 2026 at 6:59 am IST

  • Day's High

    $0.23
    $0.24

    4.35%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.16
    $1.36
    downward going graph

    28.96%

    Downside

    491.17%

    Upside

    downward going graph

Plus Therapeutics Inc share price movements today

Previous Close
$0.24
Open
$0.24
Volume
4.5M
Day's Low - High
$0.23 - $0.24
52 Week Low - High
$0.16 - $1.36

Plus Therapeutics Inc Historical Returns

1 Month Return
-24.02 %
3 Month Return
-60.34 %
1 Year Return
-80.17 %
3 Year Return
-94.37 %
5 Year Return
-99.36 %

Plus Therapeutics Inc Stock Fundamentals & Key Indicators

Check Plus Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$43.3M

EPS (TTM)

-0.1475

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.63

Industry PE ratio

0

PEG Ratio

2.4504

EBITDA

-14.9M

Revenue (TTM)

5.2M

Profit Margin

0.00%

Return On Equity TTM

-522.50%

Plus Therapeutics Inc Stock Valuation

Track how Plus Therapeutics Inc P/E has moved over time to understand its valuation trends.

Plus Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (-24.58x)

March 31, 2021

Industry (0.00x)

March 28, 2026

Today (-0.63x)

March 28, 2026

Highest (-0.37x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: -0.63x

Plus Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Plus Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Plus Therapeutics Inc image
Plus Therapeutics Inc
BUY$43.3M-99.36%-0.630.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$43.5B132.92%140.848.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.2B101.77%29.5832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.8BNA112.585.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$80.0B54.69%18.2531.41%

Stock Returns calculator for Plus Therapeutics Inc Stock including INR - Dollar returns

The Plus Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Plus Therapeutics Inc investment value today

Current value as on today

₹30,337

Returns

₹69,663

(-69.66%)

Returns from Plus Therapeutics Inc Stock

₹80,172 (-80.17%)

Dollar Returns*

₹10,509 (+10.51%)

Analyst Recommendation on Plus Therapeutics Inc Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Plus Therapeutics Inc. Average target price of $5.3

Plus Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Plus Therapeutics Inc.

What analysts predicted

95.66%UPSIDE

Target Price

$5.3

Current Price

$0.23

Analyzed by

10 Analysts

Target

$5.30

Plus Therapeutics Inc target price $5.3, a slight upside of 95.66% compared to current price of $0.23. According to 10 analysts rating.

Plus Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Plus Therapeutics Inc Stock has decreased by -47% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-47% versus previous 30 day period

Plus Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
1
1
1
1
1
1
1
1
1
1
Gross Profit
1
1
1
1
1
1
0
1
1
1
Operating Income
-3
-3
-3
-3
-3
-3
-3
-1
-4
-5
EBITDA
-2
-3
-3
0
-2
-3
-13
5
-4
-2
Interest Expense
0
0
0
3
0
0
3
-
-
4
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-3
-3
-3
-2
-2
-3
-17
5
-4
-5
Income Tax Expense
0
0
0
-
-
-
-
-
-
-
Net Income
-3
-3
-3
-2
-2
-3
-17
5
-4
-5
Net Profit Margin
-259.60%
-290.18%
-194.45%
-229.87%
-197.39%
-276.42%
-1643.15%
370.58%
-316.61%
-417.92%

Plus Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
11
6
2
6
0
-
0
4
5
5
Gross Profit
8
5
1
6
-2
0
0
-4
4
4
Operating Income
-19
-20
-8
-3
-9
-12
-19
-13
-14
-15
EBITDA
-18
-18
-6
0
-8
-12
-18
-12
-8
-14
Interest Expense
2
2
1
1
1
0
0
0
3
3
Depreciation
-
2
2
0
0
0
0
0
0
0
Income Before Tax
-22
-22
-8
-3
-8
-13
-20
-13
-12
-22
Income Tax Expense
2
2
1
9
1
0
0
-
-
-
Net Income
-22
-22
-12
-10
-8
-13
-20
-13
-12
-22
Net Profit Margin
-193.73%
-353.86%
-423.53%
-155.57%
-2719.80%
0.00%
-9051.34%
-271.04%
-222.84%
-429.43%

Plus Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-3
-3
-2
-2
-3
-17
5
-4
-5
Operating Cash Flow
-1
-4
-1
-3
-1
-6
-5
-2
-6
Investing Cash Flow
0
0
-3
0
0
3
-4
1
-1
Financing Cash Flow
0
0
6
-
-
12
2
12
2
Change in Cash
-2
-5
2
-3
-1
9
-7
11
-4

Plus Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-22
-12
-10
-8
-13
-20
-13
-12
-22
Operating Cash Flow
-18
-11
-5
-8
-10
-12
-12
-10
-20
Investing Cash Flow
-1
0
5
0
0
0
0
-4
0
Financing Cash Flow
16
7
12
0
20
13
3
6
30
Change in Cash
-2
-4
12
-9
10
0
-9
-8
8

Global Institutional Holdings in Plus Therapeutics Inc

Funds
Holdings
Scientech Research LLC
0.08%
Northern Trust Corp
0.19%
SBI Securities Co Ltd
0%
Kestra Advisory Services, LLC
0.01%
Mercer Global Advisors Inc.
0.02%
See all

Insights on Plus Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 18.2% return, outperforming this stock by 98.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 68.3% return, outperforming this stock by 162.7%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 1.39M → 1.36M (in $), with an average decrease of 2.2% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 5.15M → -5.71M (in $), with an average decrease of 107.5% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, PSTV stock has moved down by -60.3%

About Plus Therapeutics Inc

plus therapeutics, inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. its lead product candidate is doceplus, a protein-stabilized pegylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. the company is also involved in developing doxoplus, a generic pegylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and kaposi's sarcoma. it has a license agreement with nanotx, corp. to develop and commercialize nanotx's glioblastoma treatment. the company was formerly known as cytori therapeutics, inc. and changed its name to plus therapeutics, inc. in july 2019. plus therapeutics, inc. was founded in 1996 and is headquartered in austin, texas.
OrganisationPlus Therapeutics Inc
Headquarters6420 LEVIT GREEN BOULEVARD, Houston, TX, United States, 77021
IndustryHealth Technology
CEODr. Marc H. Hedrick M.B.A., M.D.
E-voting on sharesClick here to vote

Key Management of Plus Therapeutics Inc

Name

Title

Dr. Marc H. Hedrick M.B.A., M.D.

President, CEO & Director

Mr. Andrew J. Sims CPA

VP & CFO

Mr. Russ Havranek M.B.A., M.S.

Executive Vice President of Commercial and Corporate Strategy

Ms. Desiree Smith

Corporate Controller

Mr. Russell W. Bradley

President & GM of CNSide Diagnostics, LLC

FAQs

What is Plus Therapeutics Inc share price today?

Plus Therapeutics Inc share price today is $0.23 as on at the close of the market. Plus Therapeutics Inc share today touched a day high of $0.24 and a low of $0.23.

What is the 52 week high and 52 week low for Plus Therapeutics Inc share?

Plus Therapeutics Inc share touched a 52 week high of $1.36 on and a 52 week low of $0.16 on . Plus Therapeutics Inc stock price today i.e. is closed at $0.23,which is 83.08% down from its 52 week high and 40.76% up from its 52 week low.

What is Plus Therapeutics Inc's market capitalisation today?

Plus Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Plus Therapeutics Inc Stock (PSTV) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Plus Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Plus Therapeutics Inc Shares that will get you 6.5217 shares as per Plus Therapeutics Inc share price of $0.23 per share as on March 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy Plus Therapeutics Inc Stock (PSTV) from India?

Indian investors can start investing in Plus Therapeutics Inc (PSTV) shares with as little as ₹94.651 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.51 in Plus Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Plus Therapeutics Inc share’s latest price of $0.23 as on March 28, 2026 at 1:29 am IST, you will get 43.4783 shares of Plus Therapeutics Inc. Learn more about fractional shares .

What are the returns that Plus Therapeutics Inc has given to Indian investors in the last 5 years?

Plus Therapeutics Inc stock has given -99.36% share price returns and 29.26% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?